Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, insulin detemir, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 60
States / cities: Alexander City, Alabama • Birmingham, Alabama • Encino, California + 49 more

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: Insulin glulisine, insulin lispro, insulin glargine, NPH insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Work Related Upper Limb Disorder, Musculoskeletal Pain
Interventions: Education presentation of surgical ergonomics, Summary of Ergonomic Measurement System; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Multiple Myeloma
Interventions: Fludarabine monophosphate, melphalan, Bortezomib; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 69 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: Oral, Intravenous drug; Drug
Lead sponsor: Corewell Health South; Other
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Saint Joseph, Michigan

Conditions: Advanced Solid Malignancies
Interventions: CT7001, Fulvestrant; Drug
Lead sponsor: Carrick Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 12
States / cities: Tucson, Arizona • Beverly Hills, California • Tampa, Florida + 9 more

Conditions: Cognitive Function
Interventions: DCTclock; Device
Lead sponsor: Digital Cognition Technologies; Industry
Eligibility: 55 Years to 95 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Maitland, Florida

Conditions: Nausea, Postoperative
Interventions: QUEASEEase aromatherapy quick tab, Placebo product; Other
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 99 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Chronic Urticaria
Interventions: Stress intervention; Behavioral
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Facioscapulohumeral Muscular Dystrophy
Interventions: FSHD-specific functional rating scale, Electrical Impedance Myography; Diagnostic Test · Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 5 more

Conditions: Diabetes Mellitus, Type 2, Obesity
Interventions: Time restricted feeding (TRF), Daily calorie restriction; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: Abiraterone acetate; Drug
Lead sponsor: Cougar Biotechnology, Inc.; Industry
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: HIV/AIDS, Sexually Transmitted Infections
Interventions: RESPECT-2 Counseling; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 5,012 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 6 more

Conditions: Hepatic Impairment
Interventions: WCK 2349; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity
Interventions: endothelial cell collection; Other
Lead sponsor: Bettina Mittendorfer; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Healthy Subjects (HS)
Interventions: zidebactam administered as a 1g (approximately 200 μCi) IV infusion over 1 hour; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV; Drug
Lead sponsor: Carl T. Hayden VA Medical Center; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Diabetes
Interventions: Ramipril, Candesartan cilexetil, Allopurinol; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Sickle Cell Disease
Interventions: GBT440; Drug
Lead sponsor: Global Blood Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Non-Central Nervous System (CNS) Malignancies
Interventions: Oprozomib, Midazolam; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Detroit, Michigan + 4 more

Conditions: Obesity
Interventions: Weight Management Program (WMP), Medication for chronic weight management (Rx); Other · Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: CS0159; Drug
Lead sponsor: Cascade Pharmaceuticals, Inc; Other
Eligibility: 18 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Respiratory Aspiration of Gastric Contents
Interventions: Interview questionnaire, Gastric ultrasound exam; Behavioral · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: COVID - 19
Interventions: PA-001; Drug
Lead sponsor: PeptiDream Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

Evaluation and Modification of Surgeon Ergonomics in the Operation Room Using Artificial Intelligence Analytics

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

Evaluation of DCTclock™ as a Cognitive Assessment Aid

Effects of Aromatherapy on Nausea Levels

Stress Intervention for Chronic Urticaria

Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

Time Restricted Eating for the Treatment of Type 2 Diabetes

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.

Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

Routine Validation and Reproducibility Testing of Laboratory Measures and Research Techniques Used for Metabolism Research (VAL)

Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

Impact of Diabetes on Left Ventricular Remodeling

A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159

Gastric Ultrasound for Estimation of the Aspiration Risk Study

PA-001 Ph.1 Study in Healthy and Elderly Subjects